Spots Global Cancer Trial Database for fluzoparib
Every month we try and update this database with for fluzoparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | NCT05585281 | Ovarian Cancer | Fluzoparib QL1101 | 18 Years - 70 Years | Liaoning Tumor Hospital & Institute | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | NCT03509636 | Ovarian Cancer | Fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | NCT04517357 | Relapsed Ovaria... | Fluzoparib+Apat... Fluzoparib Fluzoparib+Apat... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | NCT05732129 | Homologous Reco... | Fluzoparib Irinotecan | 18 Years - 75 Years | Fudan University | |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | NCT05761470 | Her-2 Negative ... HRR Gene Mutati... | Camrelizumab Fluzoparib Nab-paclitaxel | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects | NCT04108676 | Advanced Solid ... | Fluzoparib Omeprazole | 18 Years - 50 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer | NCT05656131 | Advanced HER2 N... | Fluzoparib Fluzoparib+Camr... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | NCT03075462 | Ovarian Cancer Triple Negative... | Fluzoparib Apatinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma | NCT05952128 | Sarcoma | Fluzoparib+ Dal... | 12 Years - 75 Years | Sun Yat-sen University | |
| A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | NCT05585281 | Ovarian Cancer | Fluzoparib QL1101 | 18 Years - 70 Years | Liaoning Tumor Hospital & Institute | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial | NCT05223582 | High-risk Prost... Neoadjuvant The... | Abiraterone ace... Fluzoparib Prednisone Androgen depriv... Radical Prostat... | 18 Years - | Fudan University | |
| Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | NCT05551208 | Ovarian Cancer | fluzopanib and ... | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | NCT04229615 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Fluzoparib; Apa... Fluzoparib Placebo | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | NCT06413992 | Endometrial Car... TP53 Mutation Recurrent or Me... | Fluzoparib Camrelizumab paclitaxel (alb... Carboplatin inj... Carboplatin External irradi... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | NCT03509636 | Ovarian Cancer | Fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | NCT05891093 | Breast Cancer | Fluzoparib Anastrozole Letrozole Exemestane Tamoxifen Toremifene Abemaciclib LHRH agonist | 18 Years - 70 Years | Fudan University | |
| The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | NCT05732129 | Homologous Reco... | Fluzoparib Irinotecan | 18 Years - 75 Years | Fudan University | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma | NCT05894018 | Sarcoma,Soft Ti... Brachytherapy Poly(ADP-ribose... | Fluzoparib Radioactive par... | 18 Years - | Sun Yat-sen University | |
| A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | NCT04869488 | Metastatic Cast... | Fluzoparib Enzalutamide OR... Fluzoparib Comb... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | NCT06413992 | Endometrial Car... TP53 Mutation Recurrent or Me... | Fluzoparib Camrelizumab paclitaxel (alb... Carboplatin inj... Carboplatin External irradi... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | NCT04659785 | Small Cell Lung... | Fluzoparib Apatinib | 18 Years - 70 Years | Tianjin Medical University Second Hospital | |
| Treatment of Carrying TP53 Harmful Mutations | NCT03645200 | Advanced Cancer | Fluzoparib comb... | 18 Years - 70 Years | Tianjin Medical University Second Hospital | |
| A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | NCT05170594 | Ovarian Cancer | Bevacizumab chemotherapy Fluzoparib | 18 Years - 75 Years | The Second Affiliated Hospital of Shandong First Medical University | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | NCT04229615 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Fluzoparib; Apa... Fluzoparib Placebo | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | NCT05761470 | Her-2 Negative ... HRR Gene Mutati... | Camrelizumab Fluzoparib Nab-paclitaxel | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | NCT04296370 | Treatment in HE... | Fluzoparib; Apa... Fluzoparib Physician's cho... | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer | NCT04425876 | Pancreatic Canc... | Fluzoparib | 18 Years - 79 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Food-Effect and Metabolism Study in Healthy Subjects | NCT03062982 | Solid Tumor | Fluzoparib | 18 Years - 50 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | NCT04296370 | Treatment in HE... | Fluzoparib; Apa... Fluzoparib Physician's cho... | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer | NCT04828395 | Non-small Cell ... | Camrelizumab Fluzoparib Cisplatin，Pemet... Cisplatin，Etopo... Carboplatin, Al... Radiotherapy | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | NCT04517357 | Relapsed Ovaria... | Fluzoparib+Apat... Fluzoparib Fluzoparib+Apat... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | NCT04400188 | Small Cell Lung... | Fluzoparib temozolomide SHR-1316 | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma | NCT04535687 | Renal Cell Carc... | Fluzoparib | 18 Years - 120 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer | NCT04828395 | Non-small Cell ... | Camrelizumab Fluzoparib Cisplatin，Pemet... Cisplatin，Etopo... Carboplatin, Al... Radiotherapy | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
